Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer.
10.4048/jbc.2015.18.3.271
- Author:
Hyun Ah KIM
1
;
Min Ki SEONG
;
Eun Kyu KIM
;
Eunyoung KANG
;
Seho PARK
;
Min Hee HUR
;
Byung Joo SONG
;
Woo Chul NOH
Author Information
1. Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Korea. nohwoo@kcch.re.kr
- Publication Type:Original Article
- Keywords:
Adjuvant chemotherapy;
Lymph nodes;
Survival;
Triple negative breast neoplasms
- MeSH:
Breast Neoplasms;
Chemotherapy, Adjuvant;
Cyclophosphamide;
Drug Therapy*;
Fluorouracil;
Follow-Up Studies;
Humans;
Lymph Nodes;
Mastectomy, Segmental;
Methotrexate;
Multivariate Analysis;
Survival Rate;
Triple Negative Breast Neoplasms*
- From:Journal of Breast Cancer
2015;18(3):271-278
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study aimed to evaluate the survival benefit of different adjuvant chemotherapy regimens in patients with T1-2N0 triple-negative breast cancer. METHODS: Of 67,321 patients who were registered in the Korean Breast Cancer Society nationwide database between January 1999 and December 2008, 4,033 patients with T1-2N0 triple-negative breast cancer were included. The overall survival of patients who did not receive adjuvant chemotherapy was compared with those treated with adjuvant anthracycline and cyclophosphamide (AC), 5-fluorouracil, anthracycline, and cyclophosphamide (FAC), or cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). RESULTS: The median follow-up was 52.5 months. Chemotherapy was used in 87.4% of patients; it was used more commonly in patients with T2 tumors, those who were younger, had a higher histologic grade, and who showed lymphovascular invasion. The 5-year cumulative overall survival rate was 95.4%. Younger age, breast-conserving surgery, and adjuvant chemotherapy were significantly associated with improved overall survival. The 5-year cumulative overall survival rate of patients who did not receive adjuvant chemotherapy and those treated with AC, FAC, and CMF were 92.5%, 95.9%, 95.3%, and 95.9%, respectively. On multivariate analysis, the administration of any adjuvant chemotherapy regimen was significantly associated with improved overall survival (p=0.038). No significant difference in survival benefit was observed among the three different treatment groups. CONCLUSION: A standard adjuvant chemotherapy regimen with the least drug-related toxicity might be a reasonable treatment for patients with T1-2N0 triple-negative breast cancer.
